Your browser doesn't support javascript.
loading
Proteomic landscape of epithelial ovarian cancer.
Qian, Liujia; Zhu, Jianqing; Xue, Zhangzhi; Zhou, Yan; Xiang, Nan; Xu, Hong; Sun, Rui; Gong, Wangang; Cai, Xue; Sun, Lu; Ge, Weigang; Liu, Yufeng; Su, Ying; Lin, Wangmin; Zhan, Yuecheng; Wang, Junjian; Song, Shuang; Yi, Xiao; Ni, Maowei; Zhu, Yi; Hua, Yuejin; Zheng, Zhiguo; Guo, Tiannan.
Affiliation
  • Qian L; School of Medicine, Westlake University, Hangzhou, Zhejiang Province, China.
  • Zhu J; Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang Province, China.
  • Xue Z; Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
  • Zhou Y; Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
  • Xiang N; Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
  • Xu H; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Sun R; School of Medicine, Westlake University, Hangzhou, Zhejiang Province, China.
  • Gong W; Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang Province, China.
  • Cai X; Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
  • Sun L; Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
  • Ge W; School of Medicine, Westlake University, Hangzhou, Zhejiang Province, China.
  • Liu Y; Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang Province, China.
  • Su Y; Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
  • Lin W; Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
  • Zhan Y; School of Medicine, Westlake University, Hangzhou, Zhejiang Province, China.
  • Wang J; Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang Province, China.
  • Song S; Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
  • Yi X; Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
  • Ni M; MOE Key Laboratory of Biosystems Homeostasis and Protection, Institute of Biophysics, College of Life Science, Zhejiang University, Hangzhou, China.
  • Zhu Y; School of Medicine, Westlake University, Hangzhou, Zhejiang Province, China.
  • Hua Y; Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang Province, China.
  • Zheng Z; Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
  • Guo T; Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Nat Commun ; 15(1): 6462, 2024 Jul 31.
Article de En | MEDLINE | ID: mdl-39085232
ABSTRACT
Epithelial ovarian cancer (EOC) is a deadly disease with limited diagnostic biomarkers and therapeutic targets. Here we conduct a comprehensive proteomic profiling of ovarian tissue and plasma samples from 813 patients with different histotypes and therapeutic regimens, covering the expression of 10,715 proteins. We identify eight proteins associated with tumor malignancy in the tissue specimens, which are further validated as potential circulating biomarkers in plasma. Targeted proteomics assays are developed for 12 tissue proteins and 7 blood proteins, and machine learning models are constructed to predict one-year recurrence, which are validated in an independent cohort. These findings contribute to the understanding of EOC pathogenesis and provide potential biomarkers for early detection and monitoring of the disease. Additionally, by integrating mutation analysis with proteomic data, we identify multiple proteins related to DNA damage in recurrent resistant tumors, shedding light on the molecular mechanisms underlying treatment resistance. This study provides a multi-histotype proteomic landscape of EOC, advancing our knowledge for improved diagnosis and treatment strategies.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protéines / Protéome / Carcinome épithélial de l'ovaire Limites: Adult / Female / Humans / Middle aged Pays/Région comme sujet: Asia Langue: En Journal: Nat Commun Sujet du journal: BIOLOGIA / CIENCIA Année: 2024 Type de document: Article Pays d'affiliation: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protéines / Protéome / Carcinome épithélial de l'ovaire Limites: Adult / Female / Humans / Middle aged Pays/Région comme sujet: Asia Langue: En Journal: Nat Commun Sujet du journal: BIOLOGIA / CIENCIA Année: 2024 Type de document: Article Pays d'affiliation: Chine